Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01255800 · ClinicalTrials.gov registry record · Phase 1
Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer
A Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01255800 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 9 participants.
The verdict
NCT01255800, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study will evaluate the clinical activity of the combination of ipilimumab (IPI) -926 in combination with cetuximab in patients with advanced head and neck cancer.
Interventions
- DRUG IPI-926 and Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2011-04 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01255800
The ClinicalTrials.gov registry entry for NCT01255800 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IPI-926 and Cetuximab is the first listed.
NCT01255800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01255800 about?
NCT01255800 is a clinical study titled "Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer". This study will evaluate the clinical activity of the combination of ipilimumab (IPI) -926 in combination with cetuximab in patients with advanced head and neck cancer.
What is the current status of trial NCT01255800?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2011-04. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01255800?
The interventions under investigation include: IPI-926 and Cetuximab (DRUG).
Who is sponsoring clinical trial NCT01255800?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.